Advancing powder compaction analysis with the new Gamlen D series
D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles.
Designed for advanced tableting research, Gamlen Tableting’s new flagship D series dynamic powder compaction analysers feature dwell time control from 90 milliseconds to 60 seconds. D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles including strain data, Heckel and Kawakita plots. An optional add-on, the Tablet Tensile Analyzer (TTA), automatically calculates tablet density and solid fraction, and tablet tensile fracture stress.
Michael Gamlen, Managing Director, commented: “The D-series will change the way scientists characterise materials. The key element of the D series is our unique dynamic compaction analysis software, which allows researchers to characterise the elasticity and plasticity of materials at each compaction event, as well as their lubricity and punch detachment behaviour. This is in addition to recording, in real-time, compaction and ejection profiles of an API, excipient, or drug formulation. Researchers will now be able to create a database of material-specific data to support a wide variety of investigations, such as screening for compatible excipients, and enabling accelerated formulation and process development and scale-up to manufacturing.”
Tablet tensile strength can be measured on a D-series instrument via an included high-sensitivity load cell, or alternatively by using the Gamlen Tablet Tensile Analyzer. The Gamlen Tablet Tensile Analyzer is a complementary stand-alone system which measures tablet fracture stress properties in addition to out-of-die weight and thickness of a tablet produced on a D-series instrument. The included TTA software package automatically captures all of these parameters and produces Compaction Triangle plots of compactibility, compressibility, and tabletability.
With a rapidly expanding product range, Gamlen Tableting has transformed the entire Gamlen product line to include the Gamlen M series, for small-scale manufacture of tablets under tightly controlled conditions, and the R series (formerly known as the GTP-1) to support fundamental tableting research and development in a university or company environment.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance